Julie Chang

2.9k total citations
44 papers, 806 citations indexed

About

Julie Chang is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Julie Chang has authored 44 papers receiving a total of 806 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pathology and Forensic Medicine, 19 papers in Genetics and 15 papers in Oncology. Recurrent topics in Julie Chang's work include Lymphoma Diagnosis and Treatment (25 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Lung Cancer Treatments and Mutations (6 papers). Julie Chang is often cited by papers focused on Lymphoma Diagnosis and Treatment (25 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Lung Cancer Treatments and Mutations (6 papers). Julie Chang collaborates with scholars based in United States, Canada and Australia. Julie Chang's co-authors include Minesh P. Mehta, H. Ian Robins, Brad S. Kahl, Deepak Khuntia, David MacDonald, Doreen M. Hallman, David Simpson, Richard van der Jagt, Ian W. Flinn and John M. Burke and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Julie Chang

43 papers receiving 789 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Julie Chang United States	14	383	379	261	194	176	44	806
Hari Menon India	14	233 0.6×	176 0.5×	214 0.8×	119 0.6×	189 1.1×	73	633
Mihaela Munteanu United States	14	538 1.4×	548 1.4×	339 1.3×	195 1.0×	107 0.6×	61	1.1k
Reem Karmali United States	17	559 1.5×	647 1.7×	192 0.7×	137 0.7×	130 0.7×	116	1.0k
Jakob Werner Hansen Denmark	13	264 0.7×	414 1.1×	260 1.0×	216 1.1×	88 0.5×	39	822
Ciara L. Freeman United States	15	451 1.2×	335 0.9×	173 0.7×	279 1.4×	83 0.5×	87	934
Nili Peylan‐Ramu Israel	14	240 0.6×	157 0.4×	210 0.8×	243 1.3×	327 1.9×	24	956
Sarah M. Larson United States	14	343 0.9×	201 0.5×	200 0.8×	180 0.9×	89 0.5×	74	749
Craig A. Portell United States	16	322 0.8×	409 1.1×	281 1.1×	154 0.8×	50 0.3×	65	765
Paolo Gavarotti Italy	17	315 0.8×	501 1.3×	130 0.5×	126 0.6×	158 0.9×	36	829
Giulia Cervetti Italy	14	252 0.7×	341 0.9×	265 1.0×	63 0.3×	105 0.6×	37	615

Countries citing papers authored by Julie Chang

Since Specialization

Citations

This map shows the geographic impact of Julie Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Chang more than expected).

Fields of papers citing papers by Julie Chang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Chang. The network helps show where Julie Chang may publish in the future.

Co-authorship network of co-authors of Julie Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Julie Chang. A scholar is included among the top collaborators of Julie Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Chang. Julie Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chang, Julie, et al.. (2025). Enhancing gastroenterology with multimodal learning: the role of large language model chatbots in digestive endoscopy. Frontiers in Medicine. 12. 1583514–1583514. 3 indexed citations

Lynn, Kendra J., John David Rhodes, Frank A. Trusdell, et al.. (2023). Time-series petrologic and geochemical monitoring of the 2022 eruption of Mauna Loa, Hawai‘i. 1 indexed citations

Jagadeesh, Deepa, Stefan K. Barta, Jonathan E. Brammer, et al.. (2023). A Multicenter Real-World Analysis (RWA) of Primary Cutaneous Anaplastic Large Cell Lymphoma (PCALCL) Treated in the Modern Era. Blood. 142(Supplement 1). 6177–6177. 1 indexed citations

Baron, Michael, et al.. (2022). Geriatric Craniomaxillofacial Fractures: Where do They Happen and Why?. Journal of Oral and Maxillofacial Surgery. 80(10). 1655–1662. 1 indexed citations

Gregory, Gareth P., Shaji Kumar, Ding Wang, et al.. (2021). Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. Blood Advances. 6(4). 1232–1242. 24 indexed citations

Evens, Andrew M., Fangxin Hong, Thomas M. Habermann, et al.. (2020). A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. Clinical Cancer Research. 26(17). 4468–4477. 16 indexed citations

Scales, Suzie J., Siao Ping Tsai, Neelie T. Zacharias, et al.. (2019). Development of a Cysteine-Conjugatable Disulfide FRET Probe: Influence of Charge on Linker Cleavage and Payload Trafficking for an Anti-HER2 Antibody Conjugate. Bioconjugate Chemistry. 30(12). 3046–3056. 8 indexed citations

D’Angelo, Christopher R., et al.. (2019). Intravascular large B-cell lymphoma presenting with altered mental status: A case report. World Journal of Clinical Oncology. 10(12). 402–408. 4 indexed citations

Evens, Andrew M., Fangxin Hong, Thomas M. Habermann, et al.. (2017). A 3-Arm Randomized Phase II Trial with Bendamustine/Rituximab Therapy in Untreated High Risk (HR) Follicular Lymphoma (FL): Bortezomib Induction or Novel IMiD® Continuation (BIONIC) Study from the ECOG-ACRIN Cancer Research Group. Blood. 130. 482–482. 4 indexed citations

10.

Kahl, Brad S., John M. Burke, Richard van der Jagt, et al.. (2017). Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial. Blood. 130. 484–484. 10 indexed citations

11.

Flinn, Ian W., Richard van der Jagt, Julie Chang, et al.. (2017). FIRST‐LINE TREATMENT OF INHL OR MCL PATIENTS WITH BR OR R‐CHOP/R‐CVP: RESULTS OF THE BRIGHT 5‐YEAR FOLLOW‐UP STUDY. Hematological Oncology. 35(S2). 140–141. 9 indexed citations

12.

Wilson, Wyndham H., Brandelyn N. Pitcher, Eric D. Hsi, et al.. (2016). Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303. Blood. 128(22). 469–469. 70 indexed citations

13.

Chang, Julie, et al.. (2014). Pain Assessment in Children. Clinical Journal of Pain. 31(3). 189–197. 35 indexed citations

14.

Angevin, Eric, José A. López-Martín, Chia‐Chi Lin, et al.. (2013). Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma. Clinical Cancer Research. 19(5). 1257–1268. 103 indexed citations

15.

Martin, Peter, Julie Chang, Robert M. Rifkin, et al.. (2012). MLN9708, an investigational proteasome inhibitor, in patients (pts) with relapsed/refractory lymphoma: Emerging data from a phase I dose-escalation study.. Journal of Clinical Oncology. 30(15_suppl). 8064–8064. 2 indexed citations

16.

Cassaday, Ryan D., Jeffrey Malik, & Julie Chang. (2011). Regression of Hodgkin Lymphoma After Discontinuation of a Tumor Necrosis Factor Inhibitor for Crohn's Disease: A Case Report and Review of the Literature. Clinical Lymphoma Myeloma & Leukemia. 11(3). 289–292. 20 indexed citations

17.

Chang, Julie, Jae Werndli, Wayne A. Bottner, et al.. (2010). Rituximab and CHOP Chemotherapy Plus GM-CSF for Previously Untreated Diffuse Large B-Cell Lymphoma in the Elderly: A Wisconsin Oncology Network Study. Clinical Lymphoma Myeloma & Leukemia. 10(5). 379–384. 13 indexed citations

18.

Rossi, Davide, Valeria Spina, Clara Deambrogi, et al.. (2009). TP53 Mutations, the Most Frequent Genetic Lesion in Richter Syndrome, Represent An Independent Predictor of Survival Post Transformation.. Blood. 114(22). 670–670. 5 indexed citations

19.

Chang, Julie, Brad S. Kahl, Walter Longo, et al.. (2008). Augmented and standard Berlin–Frankfurt–Münster chemotherapy for treatment of adult acute lymphoblastic leukemia. Leukemia & lymphoma. 49(12). 2298–2307. 38 indexed citations

20.

Chang, Julie, Mark Juckett, Natalie S. Callander, et al.. (2008). Thalidomide Maintenance Following High-Dose Melphalan with Autologous Stem Cell Support in Myeloma. Clinical Lymphoma & Myeloma. 8(3). 153–158. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact